Clinical pathological features of the 146 patients included in the tissue microarray
| Clinicopathologic Features . | Patients, no. . | % . | Median (range) . |
|---|---|---|---|
| Sex | |||
| Male | 86 | 58.9 | – |
| Female | 60 | 41.1 | – |
| Age at surgery, y | – | – | 39 (18–70) |
| KPS | 100 (80–100) | ||
| Preoperative volume (cc) | – | – | 47 (6–260) |
| ΔVT2T1 category (cc) | 15 (0–84) | ||
| Proliferative tumoral pattern, ΔVT2T1 <15 cm3, n (%) | 67 | 45.9 | |
| Infiltrative tumoral pattern, ΔVT2T1 ≥ 15 cm3, n (%) | 79 | 54.1 | |
| Postoperative volume (cc) | – | – | 8 (0–125) |
| EOR (%) | – | – | 86 (49–100) |
| Histology (WHO 2007) | |||
| Astrocytoma | 80 | 54.8 | – |
| Oligodendroglioma | 19 | 13.0 | – |
| Oligoastrocytoma | 47 | 32.2 | – |
| WHO 2016 classification | |||
| Diffuse astrocytoma IDH mutant | 81 | 55.5 | – |
| Diffuse astrocytoma IDH wild type | 8 | 5.5 | – |
| Oligodendroglioma IDH mutant and 1p/19q codeleted | 57 | 39.0 | – |
| Molecular class | |||
| IDH wild type | 8 | 5.5 | – |
| IDH1/2 mutation only | 81 | 55.5 | – |
| IDH1/2 mutation and 1p/19q codeletion | 57 | 39.4 | – |
| Ki67 expression (%) | 5 (1–20) | ||
| ≤4 | 71 | 48.6 | – |
| >4 | 75 | 51.4 | – |
| Number of mitoses / 10 high power fields | – | – | 1 (0–10) |
| P53 expression (%) (n = 144) | 40 (0–100) | ||
| ATRX downregulation (n = 141) | 73 | 51.8 | |
| IDH1 mutation | 134 | 91.8 | – |
| IDH2 mutation | 4 | 2.7 | – |
| IDH1 or IDH2 mutation | 138 | 94.5 | – |
| Chromosome 1p deletion | 58 | 39.7 | – |
| Chromosome 19q deletion | 69 | 47.3 | – |
| Chromosome 1p and 19q codeletion | 57 | 39.0 | – |
| MGMT promoter methylation | 135 | 93.8 | – |
| Clinicopathologic Features . | Patients, no. . | % . | Median (range) . |
|---|---|---|---|
| Sex | |||
| Male | 86 | 58.9 | – |
| Female | 60 | 41.1 | – |
| Age at surgery, y | – | – | 39 (18–70) |
| KPS | 100 (80–100) | ||
| Preoperative volume (cc) | – | – | 47 (6–260) |
| ΔVT2T1 category (cc) | 15 (0–84) | ||
| Proliferative tumoral pattern, ΔVT2T1 <15 cm3, n (%) | 67 | 45.9 | |
| Infiltrative tumoral pattern, ΔVT2T1 ≥ 15 cm3, n (%) | 79 | 54.1 | |
| Postoperative volume (cc) | – | – | 8 (0–125) |
| EOR (%) | – | – | 86 (49–100) |
| Histology (WHO 2007) | |||
| Astrocytoma | 80 | 54.8 | – |
| Oligodendroglioma | 19 | 13.0 | – |
| Oligoastrocytoma | 47 | 32.2 | – |
| WHO 2016 classification | |||
| Diffuse astrocytoma IDH mutant | 81 | 55.5 | – |
| Diffuse astrocytoma IDH wild type | 8 | 5.5 | – |
| Oligodendroglioma IDH mutant and 1p/19q codeleted | 57 | 39.0 | – |
| Molecular class | |||
| IDH wild type | 8 | 5.5 | – |
| IDH1/2 mutation only | 81 | 55.5 | – |
| IDH1/2 mutation and 1p/19q codeletion | 57 | 39.4 | – |
| Ki67 expression (%) | 5 (1–20) | ||
| ≤4 | 71 | 48.6 | – |
| >4 | 75 | 51.4 | – |
| Number of mitoses / 10 high power fields | – | – | 1 (0–10) |
| P53 expression (%) (n = 144) | 40 (0–100) | ||
| ATRX downregulation (n = 141) | 73 | 51.8 | |
| IDH1 mutation | 134 | 91.8 | – |
| IDH2 mutation | 4 | 2.7 | – |
| IDH1 or IDH2 mutation | 138 | 94.5 | – |
| Chromosome 1p deletion | 58 | 39.7 | – |
| Chromosome 19q deletion | 69 | 47.3 | – |
| Chromosome 1p and 19q codeletion | 57 | 39.0 | – |
| MGMT promoter methylation | 135 | 93.8 | – |
Clinical pathological features of the 146 patients included in the tissue microarray
| Clinicopathologic Features . | Patients, no. . | % . | Median (range) . |
|---|---|---|---|
| Sex | |||
| Male | 86 | 58.9 | – |
| Female | 60 | 41.1 | – |
| Age at surgery, y | – | – | 39 (18–70) |
| KPS | 100 (80–100) | ||
| Preoperative volume (cc) | – | – | 47 (6–260) |
| ΔVT2T1 category (cc) | 15 (0–84) | ||
| Proliferative tumoral pattern, ΔVT2T1 <15 cm3, n (%) | 67 | 45.9 | |
| Infiltrative tumoral pattern, ΔVT2T1 ≥ 15 cm3, n (%) | 79 | 54.1 | |
| Postoperative volume (cc) | – | – | 8 (0–125) |
| EOR (%) | – | – | 86 (49–100) |
| Histology (WHO 2007) | |||
| Astrocytoma | 80 | 54.8 | – |
| Oligodendroglioma | 19 | 13.0 | – |
| Oligoastrocytoma | 47 | 32.2 | – |
| WHO 2016 classification | |||
| Diffuse astrocytoma IDH mutant | 81 | 55.5 | – |
| Diffuse astrocytoma IDH wild type | 8 | 5.5 | – |
| Oligodendroglioma IDH mutant and 1p/19q codeleted | 57 | 39.0 | – |
| Molecular class | |||
| IDH wild type | 8 | 5.5 | – |
| IDH1/2 mutation only | 81 | 55.5 | – |
| IDH1/2 mutation and 1p/19q codeletion | 57 | 39.4 | – |
| Ki67 expression (%) | 5 (1–20) | ||
| ≤4 | 71 | 48.6 | – |
| >4 | 75 | 51.4 | – |
| Number of mitoses / 10 high power fields | – | – | 1 (0–10) |
| P53 expression (%) (n = 144) | 40 (0–100) | ||
| ATRX downregulation (n = 141) | 73 | 51.8 | |
| IDH1 mutation | 134 | 91.8 | – |
| IDH2 mutation | 4 | 2.7 | – |
| IDH1 or IDH2 mutation | 138 | 94.5 | – |
| Chromosome 1p deletion | 58 | 39.7 | – |
| Chromosome 19q deletion | 69 | 47.3 | – |
| Chromosome 1p and 19q codeletion | 57 | 39.0 | – |
| MGMT promoter methylation | 135 | 93.8 | – |
| Clinicopathologic Features . | Patients, no. . | % . | Median (range) . |
|---|---|---|---|
| Sex | |||
| Male | 86 | 58.9 | – |
| Female | 60 | 41.1 | – |
| Age at surgery, y | – | – | 39 (18–70) |
| KPS | 100 (80–100) | ||
| Preoperative volume (cc) | – | – | 47 (6–260) |
| ΔVT2T1 category (cc) | 15 (0–84) | ||
| Proliferative tumoral pattern, ΔVT2T1 <15 cm3, n (%) | 67 | 45.9 | |
| Infiltrative tumoral pattern, ΔVT2T1 ≥ 15 cm3, n (%) | 79 | 54.1 | |
| Postoperative volume (cc) | – | – | 8 (0–125) |
| EOR (%) | – | – | 86 (49–100) |
| Histology (WHO 2007) | |||
| Astrocytoma | 80 | 54.8 | – |
| Oligodendroglioma | 19 | 13.0 | – |
| Oligoastrocytoma | 47 | 32.2 | – |
| WHO 2016 classification | |||
| Diffuse astrocytoma IDH mutant | 81 | 55.5 | – |
| Diffuse astrocytoma IDH wild type | 8 | 5.5 | – |
| Oligodendroglioma IDH mutant and 1p/19q codeleted | 57 | 39.0 | – |
| Molecular class | |||
| IDH wild type | 8 | 5.5 | – |
| IDH1/2 mutation only | 81 | 55.5 | – |
| IDH1/2 mutation and 1p/19q codeletion | 57 | 39.4 | – |
| Ki67 expression (%) | 5 (1–20) | ||
| ≤4 | 71 | 48.6 | – |
| >4 | 75 | 51.4 | – |
| Number of mitoses / 10 high power fields | – | – | 1 (0–10) |
| P53 expression (%) (n = 144) | 40 (0–100) | ||
| ATRX downregulation (n = 141) | 73 | 51.8 | |
| IDH1 mutation | 134 | 91.8 | – |
| IDH2 mutation | 4 | 2.7 | – |
| IDH1 or IDH2 mutation | 138 | 94.5 | – |
| Chromosome 1p deletion | 58 | 39.7 | – |
| Chromosome 19q deletion | 69 | 47.3 | – |
| Chromosome 1p and 19q codeletion | 57 | 39.0 | – |
| MGMT promoter methylation | 135 | 93.8 | – |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
